Future Fertility announces new strategic partnership with Eugin Group Spain

Future Fertility, the pioneer in AI-powered oocyte quality assessment, has announced a new strategic partnership with Eugin Group’s Spain-based fertility clinics.

Under this agreement, Future Fertility’s MAGENTA™ tool will be validated in the Eugin clinics, and personalised oocyte assessment reports will be commercially available to egg freezing and IVF-ICSI patients at both the Eugin Barcelona and Eugin Madrid locations.

Eugin Group is a leading global network of fertility clinics operating in Europe and Latin America, with a reputation for leadership in scientific research and the use of state-of-the-art technologies to advance patient care.

With headquarters based in Spain, a country renowned for its deep history of advancing fertility research and patient care, Eugin Group’s decision to implement Future Fertility’s technology in its flagship clinics signals increasing industry-wide confidence in their AI-based tools.

Future Fertility’s technology gained significant momentum within the fertility industry in 2023, with an installed base of over 90 clinics across more than 20 countries.

With an ability to seamlessly integrate into all laboratory set-ups, including time-lapse and microscope-only, adoption of their tools has been drastically increasing across the industry, as the dataset has grown to over 120,000 oocyte images and affiliated outcomes. With the broader adoption of these tools, the standard of care for evaluating oocyte quality is also evolving.

Historically, fertility specialists could only provide a general estimate of a patient’s chance of success based on their age and the number of mature eggs retrieved.

Future Fertility’s Deep Learning model can evaluate each egg’s unique likelihood of developing into a healthy embryo based on its image, bringing a new level of personalisation to fertility care.

Mina Popovic, the group’s scientific director comments: “Future Fertility’s AI tools enable our lab teams to assess egg quality in an objective, data-driven way that wasn’t previously possible.

“The Future Fertility team has been diligent in their approach to clinical validation and ensuring their tools are also backed through peer-reviewed scientific research. This gives us confidence that these tools are here to stay, and we’re headed towards a new standard of care in oocyte quality assessment.”

“These personalised insights enable our clinical team to tailor treatment plans to each patient’s needs and provide much-needed clarity for the patient regarding what they can expect to achieve from their treatment, while enabling stronger patient counselling on next steps,” adds Amelia Rodríguez-Aranda, medical director at Eugin Group.

Eugin Group’s decision to expand Future Fertility’s tools to its Spanish clinics follows the successful implementation of this technology in another network clinic in Argentina; CEGYR, a Eugin Group clinic in Buenos Aires, recently became the first clinic globally to use Future Fertility’s oocyte assessment software on every egg freezing and IVF-ICSI cycle.

“Eugin Group is recognised as a global powerhouse in terms of quality of care across the network. We’re excited to see the clinical and scientific use cases for our tools being proven out through such an esteemed partner,” says Christy Prada, CEO of Future Fertility.

“Eugin Group’s decision to expand our partnership to their two major home base clinics really speaks for itself – it’s great to see the value that our oocyte assessment tools are creating within the industry.

“We look forward to working together to evaluate other points along the IVF journey where our tools can help to improve outcomes and the overall patient experience.”